Royalty Pharma (RPRX) Stock Forecast & Price Target

Compare

1,299 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

RPRX Analyst Ratings

Strong Buy

7 Buy

1 Hold

0 Sell

Based on 8 analysts giving stock ratings to

Royalty

Pharma

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

RPRX Stock 12 Month Forecast

Average Price Target

$51.43

▲(13.81% Upside)

Based on 8 Wall Street analysts offering 12 month price targets for Royalty Pharma in the last 3 months. The average price target is $51.43 with a high forecast of $61.00 and a low forecast of $45.00. The average price target represents a 13.81% change from the last price of $45.19.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"29":"$29","62":"$62","37.25":"$37.3","45.5":"$45.5","53.75":"$53.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":61,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$61.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":51.43,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$51.43</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":45,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$45.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[29,37.25,45.5,53.75,62],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2025","6":"Aug<br/>2025","9":"Nov<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,42.36,43.793846153846154,45.22769230769231,46.66153846153846,48.09538461538462,49.52923076923077,50.963076923076926,52.39692307692307,53.830769230769235,55.26461538461538,56.698461538461544,58.13230769230769,59.566153846153846,{"y":61,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,42.36,43.05769230769231,43.755384615384614,44.45307692307692,45.15076923076923,45.848461538461535,46.54615384615384,47.24384615384615,47.941538461538464,48.63923076923077,49.33692307692308,50.034615384615385,50.73230769230769,{"y":51.43,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,42.36,42.56307692307692,42.76615384615385,42.96923076923077,43.17230769230769,43.37538461538462,43.57846153846154,43.78153846153846,43.98461538461538,44.18769230769231,44.39076923076923,44.59384615384615,44.79692307692308,{"y":45,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":30.803,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.031,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.605,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.892,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.876,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.466,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.682,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.78,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.118,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.332,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.9,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.64,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42.36,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$61.00

Average Price Target$51.43

Lowest Price Target$45.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Asad Haider

Goldman Sachs

$45→$51

Buy

12.86%

Upside

Reiterated

02/13/26

Royalty Pharma price target raised to $51 from $45 at Goldman SachsRoyalty Pharma price target raised to $51 from $45 at Goldman Sachs

Jason Gerberry

Bank of America Securities

$54

Buy

19.50%

Upside

Reiterated

02/12/26

Bank of America Securities Keeps Their Buy Rating on Royalty Pharma (RPRX)

Terence Flynn

Morgan Stanley

$56→$61

Buy

34.99%

Upside

Reiterated

02/12/26

Royalty Pharma price target raised to $61 from $56 at Morgan StanleyRoyalty Pharma price target raised to $61 from $56 at Morgan Stanley

Umer Raffat

Evercore ISI

Hold

―

Reiterated

02/12/26

Analysts Conflicted on These Healthcare Names: Dexcom (NASDAQ: DXCM), Vertex Pharmaceuticals (NASDAQ: VRTX) and Royalty Pharma (NASDAQ: RPRX)

Chris Schott

J.P. Morgan

$50

Buy

10.64%

Upside

Reiterated

02/11/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Incyte (NASDAQ: INCY), Edwards Lifesciences (NYSE: EW) and Royalty Pharma (NASDAQ: RPRX)

Ashwani Verma

UBS

$38→$49

Buy

8.43%

Upside

Upgraded

01/30/26

Royalty Pharma upgraded to Buy from Neutral at UBSRoyalty Pharma upgraded to Buy from Neutral at UBS

Geoff Meacham

Citi

$48→$50

Buy

10.64%

Upside

Reiterated

01/28/26

Royalty Pharma price target raised to $50 from $48 at CitiRoyalty Pharma price target raised to $50 from $48 at Citi

Michael Nedelcovych

TD Cowen

$42→$45

Buy

-0.42%

Downside

Reiterated

12/11/25

TD Cowen Sticks to Their Buy Rating for Royalty Pharma (RPRX)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Asad Haider

Goldman Sachs

$45→$51

Buy

12.86%

Upside

Reiterated

02/13/26

Royalty Pharma price target raised to $51 from $45 at Goldman SachsRoyalty Pharma price target raised to $51 from $45 at Goldman Sachs

Jason Gerberry

Bank of America Securities

$54

Buy

19.50%

Upside

Reiterated

02/12/26

Bank of America Securities Keeps Their Buy Rating on Royalty Pharma (RPRX)

Terence Flynn

Morgan Stanley

$56→$61

Buy

34.99%

Upside

Reiterated

02/12/26

Royalty Pharma price target raised to $61 from $56 at Morgan StanleyRoyalty Pharma price target raised to $61 from $56 at Morgan Stanley

Umer Raffat

Evercore ISI

Hold

―

Reiterated

02/12/26

Analysts Conflicted on These Healthcare Names: Dexcom (NASDAQ: DXCM), Vertex Pharmaceuticals (NASDAQ: VRTX) and Royalty Pharma (NASDAQ: RPRX)

Chris Schott

J.P. Morgan

$50

Buy

10.64%

Upside

Reiterated

02/11/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Incyte (NASDAQ: INCY), Edwards Lifesciences (NYSE: EW) and Royalty Pharma (NASDAQ: RPRX)

Ashwani Verma

UBS

$38→$49

Buy

8.43%

Upside

Upgraded

01/30/26

Royalty Pharma upgraded to Buy from Neutral at UBSRoyalty Pharma upgraded to Buy from Neutral at UBS

Geoff Meacham

Citi

$48→$50

Buy

10.64%

Upside

Reiterated

01/28/26

Royalty Pharma price target raised to $50 from $48 at CitiRoyalty Pharma price target raised to $50 from $48 at Citi

Michael Nedelcovych

TD Cowen

$42→$45

Buy

-0.42%

Downside

Reiterated

12/11/25

TD Cowen Sticks to Their Buy Rating for Royalty Pharma (RPRX)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Royalty Pharma

3 Months

xxx

Success Rate

5/6 ratings generated profit

Average Return

+6.20%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 83.33% of your transactions generating a profit, with an average return of +6.20% per trade.

1 Year

Michael NedelcovychTD Cowen

Success Rate

6/6 ratings generated profit

Average Return

+29.43%

reiterated a buy rating 2 months ago

Copying Michael Nedelcovych's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +29.43% per trade.

2 Years

xxx

Success Rate

6/6 ratings generated profit

Average Return

+31.62%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +31.62% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

RPRX Analyst Recommendation Trends

Rating

Oct 25

Nov 25

Dec 25

Jan 26

Feb 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, RPRX has received 23 Buy Ratings, 3 Hold Ratings, and 0 Sell Ratings. RPRX average Analyst price target in the past 3 months is 51.43.

Each month's total comprises the sum of three months' worth of ratings.

RPRX Financial Forecast

RPRX Earnings Forecast

Next quarter’s earnings estimate for RPRX is $1.07 with a range of $0.67 to $1.28. The previous quarter’s EPS was $1.47. RPRX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year RPRX has Performed in-line its overall industry.

RPRX Sales Forecast

Next quarter’s sales forecast for RPRX is $820.87M with a range of $668.72M to $934.88M. The previous quarter’s sales results were $622.00M. RPRX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year RPRX has Performed in-line its overall industry.

RPRX Stock Forecast FAQ

What is RPRX’s average 12-month price target, according to analysts?

Based on analyst ratings, Royalty Pharma PLC’s 12-month average price target is 51.43.

What is RPRX’s upside potential, based on the analysts’ average price target?

Royalty Pharma PLC has 13.81% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is RPRX a Buy, Sell or Hold?

Royalty Pharma PLC has a consensus rating of Strong Buy which is based on 7 buy ratings, 1 hold ratings and 0 sell ratings.

What is Royalty Pharma PLC’s price target?

The average price target for Royalty Pharma PLC is 51.43. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $61.00 ,the lowest forecast is $45.00. The average price target represents 13.81% Increase from the current price of $45.19.

What do analysts say about Royalty Pharma PLC?

Royalty Pharma PLC’s analyst rating consensus is a Strong Buy. This is based on the ratings of 8 Wall Streets Analysts.

How can I buy shares of RPRX?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Royalty Pharma (RPRX) Stock Forecast & Price Target

RPRX Analyst Ratings

RPRX Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Royalty Pharma

RPRX Analyst Recommendation Trends

RPRX Financial Forecast

RPRX Earnings Forecast

RPRX Sales Forecast

RPRX Stock Forecast FAQ

Detailed List of Analyst Forecasts